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Gliomas are a group of primary brain tumors, the most common and aggressive subtype
of which is glioblastoma. Glioblastoma has a median survival of just 15 months after
diagnosis. Only previous exposure to ionizing radiation and particular inherited genetic
syndromes are accepted risk factors for glioma; the vast majority of cases are thought
to occur spontaneously. Previous observational studies have described associations
between several risk factors and glioma, but studies are often conflicting and whether
these associations reflect true casual relationships is unclear because observational
studies may be susceptible to confounding, measurement error and reverse causation.
Mendelian randomization (MR) is a form of instrumental variable analysis that can be
used to provide supporting evidence for causal relationships between exposures (e.g.,
risk factors) and outcomes (e.g., disease onset). MR utilizes genetic variants, such as
single nucleotide polymorphisms (SNPs), that are robustly associated with an exposure
to determine whether there is a causal effect of the exposure on the outcome. MR is less
susceptible to confounding, reverse causation and measurement errors as it is based
on the random inheritance during conception of genetic variants that can be relatively
accurately measured. In previous studies, MR has implicated a genetically predicted
increase in telomere length with an increased risk of glioma, and found little evidence
that obesity related factors, vitamin D or atopy are causal in glioma risk. In this review, we
describe MR and its potential use to discover and validate novel risk factors, mechanistic
factors, and therapeutic targets in glioma.
Keywords: Mendelian randomization, glioma, risk factors, genetic variant, causal inference, SNP, causal
association
THE PUBLIC HEALTH BURDEN OF GLIOMA
Malignant gliomas are responsible for approximately 80% of all malignant brain tumors, with
glioblastoma being the most prevalent histological subtype (Ostrom et al., 2014) (∼45% of all
gliomas Ostrom et al., 2014; Visser et al., 2015). Although glioma is a relatively rare cancer, with
∼9,200 cases diagnosed each year in the United Kingdom (Cancer Research United Kingdom,
2015), the disease poses a serious health burden owing to its poor prognosis. The heterogeneous
nature of the tumor cells makes the vast majority of gliomas surgically incurable (Kelly, 2010).
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Additionally, difficulty is faced as therapeutic agents need to
penetrate the blood brain barrier (Azad et al., 2015). As a
result the median survival rate of grade III gliomas is two
to 5 years (Wen and Kesari, 2008) and just 15 months
for glioblastoma (WHO grade IV) (Stupp et al., 2009).
The 5-year survival for glioma varies, from approximately
58% for ependymoma patients to approximately 5% for
glioblastoma patients (Ostrom et al., 2014; Visser et al., 2015;
Cancer Research United Kingdom, 2016).
RISK FACTORS FOR GLIOMA
Accepted Risk Factors for Glioma
The only environmental factor consistently associated with
glioma risk is moderate to high exposure to ionizing radiation,
accounting for only a small proportion of cases (Bondy et al.,
2008; Braganza et al., 2012; Urbanska et al., 2014). Evidence was
first provided from the Israeli Tinea Capitus cohort of children
who had undergone radiation therapy for a benign medical
condition (Sadetzki et al., 2005). This was supported by data from
the Childhood Cancer Survivor Study that followed-up 14,361
children and adolescents (aged< 21 at initial diagnosis) who had
survived for 5 years (Neglia et al., 2006). During follow-up, 40
gliomas were diagnosed, compared to an anticipated incidence of
4.62 (standardized incidence ratios (SIR) = 8.66, 95% confidence
interval (CI) 6.24–11.6). These gliomas arose at a median of
9 years after original diagnosis. In a case-control analysis (with
4 controls per case, matched on age at diagnosis, sex and time
since diagnosis, and the analysis adjusted for original cancer
diagnosis) the odds ratio (OR) for glioma amongst children who
underwent radiation therapy vs. those who did not was 6.78 (95%
CI 1.54–29.7) (Neglia et al., 2006). The authors found that the
risk of glioma per Gray of radiation was greatest among children
who received radiation therapy at less than 5 years of age. After
adjustment for radiation dose, neither original cancer diagnosis
nor chemotherapy was associated with risk (Neglia et al., 2006).
Taylor et al. (2010) carried out a study of 17,980 participants who
had survived at least 5 years after diagnosis of childhood cancer.
In this study the risk of glioma increased linearly with dose of
radiation (Taylor et al., 2010).
Rarely, glioma occurs in more than one family member,
indicating a genetic susceptibility. This susceptibility is most
often described within cases where inherited tumor syndromes
are present, such as Li-Fraumeni syndrome, Turcot syndrome
and neurofibromatosis type 1 (Louis et al., 2016). Kinnersley
et al. (2018) reviewed glioma genome wide association study
(GWAS) and summarized reported associations at the 27 glioma-
risk SNPs (Kinnersley et al., 2018); genetic susceptibility loci are
summarized in Table 1. These risk variants contribute to an
increase in glioma risk; however, additional somatic mutations
are a requisite for tumorigenesis in individuals with these
germline variants or familial syndromes (Rice et al., 2016).
Other Postulated Risk Factors
There have been several risk factors that have been linked to the
occurrence of glioma, though results from these investigations
may be spurious because of the biases that pervade observational
studies (Louis et al., 2016). A recently published systematic review
presents risk factors for glioma onset that are shown to increase,
decrease or have a null association with glioma risk (Quach et al.,
2017).
Observational studies suggest that allergies (asthma, eczema,
hay fever) are associated with lower glioma risk (Wigertz
et al., 2007; Berg-Beckhoff et al., 2009; Amirian et al.,
2016; Wang et al., 2016) and, consistent with this, asthma-
susceptibility genotypes are associated with a reduced risk
of glioma (Schwartzbaum et al., 2005). Short term use of
anti-inflammatory medicine has also been reported to reduce
glioma risk (Scheurer et al., 2011); although other studies have
found conflicting results (Daugherty et al., 2011; Gaist et al.,
2013). The possible role of allergies in decreasing the risk of
glioma, including glioblastoma, may be due to an increase in
immune surveillance, which in turn may destroy damaged, pro-
cancerous cells earlier (Scheurer et al., 2011; Safaeian et al.,
2013; Zhao et al., 2014). This hypothesis is supported by
reports of a higher occurrence of glioma in HIV and AIDS
patients (Blumenthal et al., 1999; Jukich et al., 2001; Hall
and Short, 2009); as this is based on the result from a small
number of studies with small sample sizes the estimate may be
biased.
Brain tumors are observed to occur more often in Europeans
compared with individuals of an African or Asian origin
(McLendon et al., 1985; Kuratsu et al., 2001; Darefsky and
Dubrow, 2009; Ostrom et al., 2013), an observation that has
also been reported within children. Robertson et al. (2002)
investigated ethnic variation in the incidence of adult brain
cancer in 994,725 individuals over 10.5 years of follow-up. The
authors identified 373 people who developed brain cancer (232
glioblastomas, 106 astrocytomas and 35 oligodendrogliomas)
of whom 50 were of African ancestry and 323 of European
ancestry. Age adjusted incidence rates (per 100,000 race specific-
population/year) were 0.11 and 0.46 (p = 0.003) in the African
and European populations, respectively. The authors report
a significant difference in incidence rates for the three most
common gliomas and suggest that glioma is more common in
individuals of European ancestry than in individuals of African
ancestry (Robertson et al., 2002). Other studies have reported
that glioma occurs 3.5 times more often in Europeans compared
to African Americans (Davis et al., 1999). The explanation for
this observed ethnic discrepancy remains unclear and while
it is possible that a genetic difference exists between the two
groups (Mochizuki et al., 1999; Chen et al., 2001; Das et al.,
2002), detection bias cannot be ruled out (Dubrow and Darefsky,
2011).
Certain occupations are reported to be linked with a higher
risk of glioma, including physicians (Carozza et al., 2000;
Krishnan et al., 2003; Pukkala et al., 2009), firefighters (Carozza
et al., 2000; Krishnan et al., 2003) and farmers (Khuder et al.,
1998; Zheng et al., 2001). Occupational exposure to metals
such as arsenic and lead has attracted attention with respect
to brain tumors as they are able to penetrate the blood brain
barrier (Sunderman, 2001; Wang and Du, 2013; Liao et al.,
2016). Exposure to lead has been associated with glioma risk
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TABLE 1 | Summary of the genetic susceptibility loci identified by GWAS in
Europeans.
Gene SNP Alleles OR (95% CI)
TERT rs2736100 T/G 1.27 (1.19–1.37
CCDC26 rs4295627 G/T 1.36 (1.29–1.43)
CCDC26 rs891835 G/T 1.24 (1.17–1.30)
CDKN2A/B rs4977756 A/G 1.24 (1.19–1.30)
PHLDB1 rs498872 C/T 1.18 (1.13–1.24)
RTEL1 rs6010620 G/A 1.28 (1.21–1.35)
TP53 rs78378222 T/G 2.35 (1.61–3.44)
CCDC26 rs55705857 A/G 6.3 (4.6–8.8)
Near TERC rs1920116 G/A 1.30 (1.19–1.42)
VTI1A rs11196067 A/T 1.19 (1.12–1.27)
ZBTB16 rs648044 C/T 1.25 (1.17–1.34)
Intergenic rs12230172 G/A 1 1.23 (1.16–1.32)
POLR3B rs3851634 T/C 1.23 (1.15–1.32)
ETFA rs180159 G/A 1.36 (1.23–1.51)
JAK1 rs12752552 T/C 1.22 (1.15–1.31)
MDM4 rs4252707 G/A 1.19 (1.12–1.26)
AKT3 rs12076373 G/C 1.23 (1.16–1.32)
Near IDH1 rs7572263 A/G 1.20 (1.13–1.26)
LRIG1 rs11706832 A/C 1.15 (1.09–1.20)
OBFC1 rs11598018 C/A 1.14 (1.09–1.20)
Intergenic rs11233250 C/T 1.24 (1.16–1.33)
MAML2 rs7107785 T/C 1.16 (1.11–1.21)
AKAP6 rs10131032 G/A 1.33 (1.22–1.44)
Near MPG rs2562152 A/T 1.21 (1.13–1.29)
LMF1 rs3751667 C/T 1.18 (1.12–1.25)
HEATR3 rs10852606 T/C 1.18 (1.13–1.24)
SLC16A8 rs2235573 G/A 1.15 (1.10–1.20)
Near TERC rs3772190 G/A 1.11 (1.06–1.15)
TERT rs10069690 C/T 1.61 (1.53–1.69)
EGFR rs75061358 T/G 1.63 (1.50–1.76)
EGFR rs723527 A/G 1.25 (1.20–1.31)
CCDC26 rs55705857 G/A 3.39 (3.09–3.71)
CDKN2A/B rs634537 T/G 1.37 (1.31–1.43)
VTI1A rs11599775 G/A 1.16 (1.10–1.22)
ZBTB16 rs648044 A/G 1.19 (1.13–1.25)
PHLDB1 rs12803321 G/C 1.42 (1.35–1.49)
Intergenic rs1275600 T/A 1.16 (1.10–1.21)
RFX4 rs12227783 A/T 1.16 (1.08–1.24)
ETFA rs77633900 G/C 1.35 (1.25–1.46)
TP53 rs78378222 T/G 2.53 (2.19–2.91)
RTEL1 rs2297440 T/C 1.48 (1.40–1.56)
Table 1 is a modified version of Table 1 in Kinnersley et al. (2018). The table
describes the gene, the single nucleotide polymorphism (SNP), the allele and the
odds ratio (OR) and corresponding 95% confidence interval (95% CI). ORs are
reported with respect to the risk allele, highlighted in bold.
(Anttila et al., 1996; van Wijngaarden and Dosemeci, 2006) and
brain cancer mortality (Cocco et al., 1998; van Wijngaarden
and Dosemeci, 2006). In a cohort study of 1,779,646 men and
1,066,346 women aged 25–64 years at baseline and subsequently
followed for 19 years, an increased glioma risk was observed
amongst men exposed to arsenic, mercury, and petroleum
products (Navas-Acien et al., 2002). However, no relationship
of lead, cadmium, nickel, chromium and iron with glioma risk
was reported in a study of 1856 cases and 5189 controls (Parent
et al., 2017). Other studies investigating the relationship between
glioma and occupational exposure to metal (Samkange-Zeeb
et al., 2010) or lead (Rajaraman et al., 2006; Bhatti et al., 2009),
and between brain cancer more generally and lead (Lam et al.,
2007) reported no strong evidence of a causal association.
There has been speculation that certain lifestyle choices,
including alcohol intake, the use of drugs, or dietary exposure to
nitrous compounds affect the risk of glioma; however, to date the
evidence is inconclusive (Giles et al., 1994; Michaud et al., 2009;
Kyritsis et al., 2011; Little et al., 2013; Shao et al., 2016; Tamimi
and Juweid, 2017).
Mobile phone use has been speculated to be associated with
brain tumor risk (Schüz et al., 2006). However, conflicting finding
have also been reported (Frei et al., 2011). In a nationwide study
involving Danish citizens aged 30 years or older (born after 1925),
there was no evidence that mobile phone use increased brain
tumor risk (Frei et al., 2011).
Other risk factors that are not discussed here have been
investigated in relation to glioma risk, including but not limited
to: Type 1 and type 2 diabetes, body mass index, birth weight,
hypertension, height, birth weight, menarche (age at onset),
menopause (age at onset), coffee/caffeine consumption, low-
density lipoprotein cholesterol, insulin-like growth factor 1,
insulin-like growth factor binding protein, triglycerides, high-
density lipoprotein cholesterol, pesticide exposure, extremely low
frequency magnetic fields, vitamin E, A and C levels (Preston-
Martin and Mack, 1991; Kaplan et al., 1997; Houben et al., 2004;
Linos et al., 2007; Holick et al., 2010; Kabat et al., 2011; Little et al.,
2013; Malerba et al., 2013; Lee et al., 2014; Andersen et al., 2015;
Li et al., 2015; Zhou et al., 2015; Seliger et al., 2016a,b; Zhao et al.,
2016; Wiedmann et al., 2017).
OBSERVATIONAL EPIDEMIOLOGICAL
STUDIES VS. MENDELIAN
RANDOMISATION
Problems With Observational
Epidemiological Studies for
Identification of Causal Risk Factors
As described above, and in common with many other diseases,
the search for risk factors for glioma has largely been based
on observational cohort, case-control and cross-sectional studies
(Lawlor et al., 2004). Numerous cases exist of seemingly
robust observational associations between putative risk factors
and disease outcomes; however, interventions to modify these
risk factors do not produce the anticipated benefits under
randomized controlled trial (RCT) conditions (Davey Smith
and Hemani, 2014). One of the postulated reasons for this is
the susceptibility of observational (non-experimental) studies
to several biases (specifically, confounding, measurement error
and reverse causation) that can generate spurious associations
and which can be difficult to eradicate even through statistical
adjustment (Davey Smith and Hemani, 2014).
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A confounder is a factor that is a common cause of both
the disease under consideration and the exposure of interest.
Importantly, a confounder is not on the causal pathway between
the exposure and outcome (Hammer et al., 2009). For instance, in
2002 an association had been established between alcohol intake
and the incidence of 3.6% of all cancers (Boffetta et al., 2006;
Testino, 2011) but it is still uncertain whether an association
exists between any class of glioma and alcohol intake (Braganza
et al., 2014; Qi et al., 2014). An observed association between
glioma incidence and alcohol intake could be because individuals
who consume more alcohol are more likely to smoke (Hart et al.,
2010) and to adhere to an unhealthy life-style; (Sayon-Orea et al.,
2011; Bendsen et al., 2013) thus, it could be these other factors
that influence the risk of glioma rather than alcohol consumption
per se (Sergentanis et al., 2015).
Reverse causation occurs when the disease outcome precedes,
and leads to, the exposure rather than being a consequence of
the exposure (Flegal et al., 2011). For example a higher level
of blood glucose has been reported to be protective against
glioma (Kitahara et al., 2014); however, an alternative explanation
is that tumors take-up glucose, leading to low glucose levels
(Schwartzbaum et al., 2017).
Mendelian Randomization Analogous to
Randomized Control Trials (Figure 1)
Randomized controlled trials are considered the gold standard
study design for inferring causality, as successful randomization,
adequately blinded implementation of the intervention, high
rates of follow-up and intention-to-treat analysis should yield
results that are relatively free from the biases aﬄicting
observational studies (Iturrieta-Zuazo and Walter, 2015). On
the other hand, RCTs often reflect short-term exposures at one
time point in life, with limited follow-up, and participants are
usually not representative of general populations, a particularly
important issue if the priority is to identify primary prevention
targets (Meyer, 2010). Additionally, due to ethical, practical and
financial reasons, it is not feasible to randomize people to every
risk factor (Bochud and Rousson, 2010): e.g., exposure to power
lines, mobile phone use or breastfeeding.
One method to appraise causality within observational
epidemiology is the use of Mendelian randomization (MR). MR
is a type of “instrumental variable” analysis that utilizes genetic
variants, such as SNPs, that are robustly associated with an
exposure as proxies for the risk factor of interest. The aim of
MR is to strengthen causal inference in observational studies of
associations between risk factors and disease (Lawlor et al., 2008).
All MR studies make use of germline genetic data as opposed
to somatic data. Germline genetic variants tend to be randomly
distributed with respect to most human traits in the general
population. This is because of Mendel’s laws of inheritance
(segregation, independent assortment) and the fixed nature
of germline genotypes (Castle, 1903). Thus, germline genetic
variants are less likely to be affected by the sorts of confounding
factors that typically bias observational findings (Qi, 2009).
Additionally, as germline genotype cannot be affected by the
presence of disease, the generation of spurious results through
reverse causation is avoided (Larsson et al., 2017). Germline
genetic variants can thus be regarded as randomized proxies
for an exposure of interest, in the same way that the allocation
group in an RCT is a proxy for an intervention of interest
(Figure 1). MR can exploit SNPs that are associated with
modifiable risk factors to strengthen causal inference about the
nature of relationships between risk factors and disease (Larsson
et al., 2017).
The application of MR involves three assumptions (Figure 2):
(1) the genetic variants (“instruments”) are reliably associated
with the risk factor of interest; (2) the genetic variants are
independent of confounding factors (Didelez and Sheehan, 2007;
VanderWeele et al., 2014); and (3) the genetic variants are only
associated with the disease outcome through the risk factor
of interest (Greenland, 2000; Lawlor et al., 2008). Within the
constraints of these assumptions, genetic instruments (SNPs) can
be used as proxies for a large range of cancer-related modifiable
exposures. One-sample MR is the standard application of MR.
There is one data set that contains all the data on the SNPs,
exposure, and outcome for all participants (Haycock et al., 2016).
Due to the rare nature of glioma, one-sample MR is likely to be
statistically underpowered. As a result, MR techniques have been
developed to allow analysis when genetic association studies are
conducted in two separate samples sets: one set for the exposure
of interest and one for the outcome (Inoue and Solon, 2010). This
method is referred to as two-sample MR (Hartwig et al., 2016).
Like most diseases, glioma GWAS to date have examined
genetic variation in relation to the causes of disease risk, using
case-control study designs, as opposed to disease progression
(Melin et al., 2017). The primary application of MR in glioma
research has, therefore, focused primarily on causal effects of
environmental exposures on disease risk (Walsh et al., 2015;
Haycock et al., 2017; Disney-Hogg et al., 2018a; Takahashi et al.,
2018), as opposed to survival. There are some instances where
factors are involved in both disease incidence and progression,
such as low-density lipoprotein cholesterol levels for heart disease
risk and recurrence (Ference et al., 2017), although such instances
may be exceptional. Cases do exist where a risk factor for a disease
is not implicated in progression, as has been proposed for the
relationship between folate consumption and colon cancer (Kim,
2003). Thus, current case-control GWAS of glioma risk have
the potential to inform on the underlying causal mechanisms of
disease onset but (at the current time) may be less informative for
discovering drug targets to improve glioma survival (Paternoster
et al., 2017). The latter requires case-only GWAS that examine
genetic variation in relation to disease progression, but such
studies are currently rare (Melin et al., 2017). The most probable
explanation for this is due to a research focus to determine
mechanisms that cause disease incidence and because of the
challenges inherent in collecting progression data (see section
“Future of MR in research” below). At present, a few MR studies
have been conducted that investigate progression of disease
(Brunner et al., 2017) but none in glioma progression, which
is required for the discovery of targets for improving glioma
survival (Paternoster et al., 2017).
Mendelian randomization can be used to identify and
investigate potential drug targets (Mokry et al., 2015;
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FIGURE 1 | Comparison of Mendelian randomization (MR) with randomized control trial. This demonstrates the analogy between a randomized control trial and a
Mendelian randomized study.
FIGURE 2 | MR assumptions. The diagram illustrates the three assumptions of the MR methodology.
Zheng et al., 2017). A quarter of the drugs that enter clinical
development fail due to their ineffectiveness (Ashburn and Thor,
2004; Arrowsmith and Miller, 2013). Current drug targets are
authenticated using in-vitro and animal models, but these can fail
to predict the potential benefits (or harms) in humans (Mokry
et al., 2015; Zheng et al., 2017). Nelson et al. (2015) aimed to
establish whether current genetic evidence could predict drug
mechanisms. The authors reported that opting for targets that
are genetically supported may result in twice the success rate in
clinical development (Nelson et al., 2015). MR could substantially
augment these methods (Mokry et al., 2015; Zheng et al., 2017).
The theory is that specific genetic variants can be utilized to
imitate the effects of targeting a protein pharmacologically. If the
variant codes for a potential drug target that causes an alteration
in activity of the encoded protein, the causal effect of the drug
on disease can be assessed by MR (Sofat et al., 2010; Evans
and Smith, 2015). Additionally, MR can be used to examine all
pairwise associations between serum protein levels and disease
risk (Sun et al., 2018). If a variant is identified that is robustly
associated with levels of a serum protein that display a putative
causal relationship with disease risk, methods can be employed
to search for available drugs that cause an alteration in the
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TABLE 2 | Description of statistical methods used in Mendelian randomization
analysis.
Statistical
Method
Description
Inverse-variance
weighted (IVW)
Assumes causal estimate due to each SNP is the
same (fixed effects IVW) or that if their effects differ
that their deviations are balanced (random effects
IVW) (Hemani et al., 2018). Gives an unbiased
estimate when there is no horizontal pleiotropy (fixed
effects IVW) or when horizontal pleiotropy is balanced
(random effects IVW).
Maximum likelihood
estimation (MLE)
Assumes effect of the exposure on the outcome due
to each SNP is equal (fixed effects IVW makes the
same assumption). A benefit of this method is that it
might give more reliable results when measurement
error in the SNP-exposure effect is present (Hemani
et al., 2018). Gives an unbiased estimate when there
is no horizontal pleiotropy or when horizontal
pleiotropy is balanced (but variance of the estimate
will be underestimated in the latter scenario).
Weighted median
estimate (WME)
Takes the median effect of all SNPs. Returns an
unbiased estimate if half the SNPs are valid
instruments (Hemani et al., 2018). Requires a large
number of instrumental SNPs otherwise method is
underpowered.
Mode-based
estimate (MBE)
SNPs are clustered into groups determined by
similarity of causal effects. Returns the causal effect
estimate based on the cluster that has the greatest
number of SNPs (Hemani et al., 2018). Gives an
unbiased estimate if the SNPs in the largest cluster
are valid, even if most SNPs are invalid instruments.
Requires a large number of instrumental SNPs
otherwise method is underpowered.
MR-Egger Modifies the IVW analysis by permitting a non-zero
intercept, permitting the net-horizontal pleiotropic
effect for all SNPs to be unbalanced, or directional
(Hemani et al., 2018). Gives an unbiased estimate
even if all SNPs do not adhere to instrumental variable
assumptions but requires the InSIDE (instrument
strength independent of direct effects) assumption to
be valid. Requires a large number of instrumental
SNPs otherwise method is underpowered.
Wald ratio This is the easiest method to estimate a causal effect.
Wald ratio method is appropriate when only a single
SNP is available to proxy the risk factor of interest.
However, a limitation is that it is much harder to
appraise MR assumptions with only a single SNP.
(Wald, 1940).
The statistical methods described are the inverse variance weighted (IVW),
maximum likelihood estimation (MLE), weighted median estimate (WME), mode-
based estimate (MBE) and MR-Egger.
levels of that protein (Corsello et al., 2017). As discussed, only
case-control GWAS exist at present for glioma which may be less
informative for the discovery of drug targets to improve survival
(Paternoster et al., 2017).
Table 2 provides a summary of some of the different methods
used to obtain MR estimates (Hemani et al., 2018).
Limitations of MR Pertinent to Glioma
Mendelian randomization has widely recognized limitations
(Glynn, 2010). For some exposures there is a lack of genetic
variants (SNPs) available for instrumentation (Smith and
Ebrahim, 2004). For example, ionizing radiation emitted by
mobile phones has been suggested as a risk factor for glioma
(Yang et al., 2017). However, currently no genetic variants have
been associated with exposure (or response) to ionizing radiation
and therefore MR analysis cannot be performed for this particular
risk factor (Smith, 2010).
A key limitation of MR is pleiotropy (Sheehan et al., 2008).
Pleiotropy occurs when a genetic variant has more than one
effect. If one or more of these effects influence the outcome
through pathways other than the exposure of interest (so called
horizontal pleiotropy) a core MR assumption is violated, i.e.,
that variants only exert their effect on the outcome via their
influence on the exposure of interest (Evans et al., 2013; Burgess,
2014; Bennett and Holmes, 2017; Yarmolinsky et al., 2017).
Techniques have been developed, such as MR-Egger regression,
that can quantify the amount of bias caused by horizontal
pleiotropy, as well as providing a valid causal estimate despite
the presence of horizontal pleiotropy (Bowden et al., 2015).
Another type of pleiotropy that exists is vertical pleiotropy. This
is where the genetic variants have associations with biomarkers
that are downstream of the biomarker of interest (Bennett and
Holmes, 2017). Thus, they are on the causal pathway and should
be considered as intermediates of the relationship between an
exposure and an outcome, not as confounding factors.
Mendelian randomization studies typically require large
sample sizes, an issue that can be compounded by the rare nature
of glioma. One way to increase power is to develop genetic risk
scores that contain multiple alleles to explain more of the variance
in the exposure of interest. This runs the risk of including invalid
variants, such as those that do not exert their effect on the
outcome via the exposure of interest (Evans et al., 2013; Burgess,
2014; Yarmolinsky et al., 2017), although such potential violations
of the MR assumption can be formally tested using MR-Egger
regression. Power can also be increased by using a two-sample
approach, where large case-control GWAS can be used even if
they have not measured the exposure of interest.
Limitations of MR have been discussed in detail in several
published papers (Davey Smith and Ebrahim, 2003; Smith and
Ebrahim, 2004; Lawlor et al., 2008; Sheehan et al., 2008; Bochud
and Rousson, 2010; Davey Smith, 2011b; VanderWeele et al.,
2014).
MR IN GLIOMA RESEARCH
Studies That Have Evaluated Risk
Factors for Glioma Using MR
Two-sample MR is a method that can harness information from
GWAS summary statistics and has been applied to the context of
glioma to look at several risk factors. We discuss key studies that
have used two-sample MR to investigate associations between
previously reported risk factors and glioma (Table 3).
An MR study to evaluate the causal relevance of telomere
length on the risk of cancer and non-neoplastic diseases found
that genetically predicted longer telomeres increased the risk
of glioma, while being protective for certain non-neoplastic
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TABLE 3 | Description of MR studies that have investigated the causal association between a factor and glioma risk.
Author of the study Number of glioma Risk factor of interest Main Finding
cases and controls
Haycock et al., 2017 1,130 cases and 6,294
controls
Telomere Length Risk of glioma increases per standard deviation (SD) increase in telomere (OR
5.27; 95% CI: 3.15–8.81. P = 0.01)
Walsh et al., 2015 1,130 cases and 6,294
controls
Telomere Length Risk of glioma increases monotonically with each increasing septile of telomere
length (O.R 1.12; 95% CI: 1.09–1.16. P = 3.83 × 10−12)
Takahashi et al., 2018 12,488 cases and
18,169 controls
Vitamin D levels Little evidence of any association. (OR per SD increase in Vitamin D levels 1.21;
95% CI: 0.90–1.62. P = 0.201)
Disney-Hogg et al.,
2018a
12,488 cases and
18,169 controls
Atopy For binary risk factors the results can be interpreted by risk of disease/odds
ratio for glioma per 2.7-fold increase in odds of the risk factor (exposure). No
strong evidence of any association between glioma and asthma and hay fever
(OR 0.96; 95% CI: 0.90–1.03. P = 0.248), IgE levels (OR 0.88; 0.69–1.13.
P = 0.319), or self-reported allergy (OR 1.03; 95% CI: 0.95–1.11. P = 0.534).
For atopic dermatitis an inverse association was found by IVW (OR 0.96; 95%
CI: 0.93–1.00. P = 0.041) and MLE (OR 0.96; 95% CI: 0.94–0.99. P = 0.003)
Disney-Hogg et al.,
2018b
12,488 cases and
18,169 controls
Obesity-related factors No strong evidence of any association for all factors (P = > 0.05).
diseases, such as cardiovascular diseases (Zheng et al., 2017).
The analysis employed summary genetic data for 35 cancers and
45 non-neoplastic diseases, including 1,130 glioma cases and
6,294 controls. The strongest association was for glioma (OR per
SD increase in genetically predicted telomere length was 5.27;
95% CI: 3.15–8.81) (Zheng et al., 2017). A possible explanation
for this observation is that telomere shortening may act as a
tumor suppressor, restricting the proliferative potential of cells.
Therefore, those with longer telomeres have a greater probability
of obtaining somatic mutations due to an increased proliferative
potential (Hanahan and Weinberg, 2011).
Walsh et al. (2015) also used an MR approach to establish
whether a genotypically estimated longer or shorter telomere
length was linked with an increased risk of glioma and
whether inheritance of SNPs associated with telomere length are
indicators of glioma risk. The authors accessed differences in
genotypically estimated relative telomere length in a total of 1,130
glioma patients and 6,294 controls. The average approximated
telomere length was 31bp (5.7%) longer in glioma cases compared
with controls in discovery analyses (P = 7.82 × 10−8). This
finding was supported in the replication analysis as the mean
telomere length was 27 bp (5.0%) longer in glioma cases than
controls (1.48 × 10−3). The authors reported that the risk of
glioma increases monotonically with each increasing septile of
telomere length (O.R 1.12; 95% CI: 0.90–1.62). Additionally,
the authors reported that four telomere length-associated SNPs
were significantly related with glioma risk in pooled analyses,
including those in the telomerase component genes TERC (O.R
1.14; 95% C.I. = 1.03–1.28) and TERT (O.R 1.39; 95% C.I. = 1.27–
1.52), and those in the CST complex genes OBFC1 (O.R 1.18;
95% C.I. = 1.05–1.33) and CTC1 (O.R 1.14; 95% C.I. = 1.02–
1.28). The indication of risk alleles for glioma close to TERC
and TERT that are also related with telomere length suggests
that telomerase is important in glioma formation (Walsh et al.,
2014).
Takahashi et al. (2018) used two-sample MR to investigate
whether a causal relationship exists between circulating vitamin
D and glioma risk, involving 12,488 glioma cases and 18,169
controls. The authors reported no strong evidence of a causal
relationship between vitamin D and glioma when either the
inverse-variance weighted (IVW) method (OR per SD increase
1.21, 95% CI: 0.90–1.62, P = 0.201) or the maximum likelihood
estimation (MLE) method (OR per SD increase 1.20, 95% CI:
0.98–1.48, P = 0.083) was used (Takahashi et al., 2018).
Disney-Hogg et al. (2018a) used an MR approach to evaluate
the observed inverse relationship between allergies and glioma
risk. The instrumental variables were SNPs robustly associated
with atopic dermatitis, asthma and hay fever, IgE levels, and
self-reported allergy. The study involved 12,488 cases and 18,169
controls. The authors found no significant association between
glioma and asthma, hay fever, IgE levels, or self-reported allergy.
For atopic dermatitis an inverse association was found (OR per
2.7-fold increase in odds of atopic dermatitis) by the IVW (OR
0.96, 95% CI 0.93–1.00, P = 0.041) and MLE methods (OR 0.96,
95% CI 0.94–0.99, P = 0.003), but not for weighted median
estimate (WME) and mode-based estimate (MBE) methods
(Disney-Hogg et al., 2018a), suggesting that having atopic
dermatitis reduces the risk of glioma.
Disney-Hogg et al. (2018b) carried out an MR analysis to
interrogate the observed association between obesity-related
factors and risk of glioma. The authors identified variants that
were robustly associated with 10 key obesity-related factors: 2-h
post-challenge glucose, BMI, fasting glucose, fasting insulin, HDL
cholesterol, LDL cholesterol, type-2 diabetes, total cholesterol,
triglycerides and waist-hip ratio. This study encompassed 12,488
cases and 18,169 controls. This study found little evidence
that indicated that obesity-related factors contribute to glioma
(Disney-Hogg et al., 2018b).
Potential Application of Different MR
Study Designs in Glioma Research
There are several different design strategies for MR that have
been discussed in detail by Zheng et al. (2017). The potential
application of these different MR study designs in glioma research
are outlined below.
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Improved knowledge of signaling pathways that are causally
associated glioma incidence can be helpful to design preventative
strategies and effective therapeutic targets (Wang et al., 2015).
A useful MR strategy to establish whether a molecular
intermediate plays a role in the causal pathway between a risk
factor and disease is the use of two-step MR (Relton and Davey
Smith, 2012). An improved understanding of the molecular
changes that drive glioma formation will allow for opportunities
to modify disease causing factors.
Bidirectional MR involves using instruments for both the
exposure and the outcome to assess the direction of causality: i.e.,
does the exposure cause the outcome or does the outcome cause
the exposure (Timpson et al., 2010). For instance, observational
studies have suggested that there is an inverse association between
allergies and glioma risk, but the direction and causality of the
association remains uncertain: it is not clear whether allergies
decrease the risk of glioma or whether the inverse association
arises because of suppression of the immune system by glioma
itself (Schoemaker et al., 2006).
There are cases in which genetic variants are related to
numerous correlated phenotypes (Low, 2001), for example,
genetic variants that associate with lipoprotein metabolism tend
not to correlate with just one specific lipid fraction (Wurtz et al.,
2013). As a result assessing the causal association of one specific
intermediate phenotype with disease can be challenging (Davey
Smith and Hemani, 2014). Multi-phenotype MR can be used in
these cases (Davey Smith and Hemani, 2014; Burgess et al., 2015;
Burgess and Thompson, 2015; Kemp et al., 2016). Multivariable
MR can be applied to glioma research when testing the effect of
lipids on glioma to identify the independent effect of each lipid
subtypes on glioma.
Hypothesis-driven MR has huge potential in glioma research.
Hypothesis-driven MR can validate the relationship between
a risk factor and glioma for which a causal association has
previously been reported.
In addition, hypothesis-free MR has the potential to identify
novel causal associations. Hypothesis-free MR can be used to
examine causality in complex frameworks in glioma, as a well
as a method to data mine high-dimensional studies (Evans and
Davey Smith, 2015). Haycock et al. (2017) implemented a mixture
of hypothesis-driven and hypothesis-free MR to investigate the
relationship between telomere length and 22 cancers and 32
primary non-neoplastic diseases.
Mendelian randomization-Base is a tool that improves the
accessibility of GWAS summary data for MR research (Hemani
et al., 2016). MR-Base can assist hypothesis-free testing as it
allows researchers to examine all pairwise associations to data
mine for causal relationships of interest (Davey Smith, 2011a).
Where novel associations are identified, these associations can
then be subjected to formal and extensive hypothesis-testing
studies (Evans and Smith, 2015).
Factorial MR can be used to develop therapeutic strategies to
improve glioma survival. Factorial RCT is where a participant
is either assigned to a group that obtains neither intervention,
one of the interventions, or both (Montgomery et al., 2003). In
a factorial trial the separate effects of each intervention can be
considered, as well as, the benefits of obtaining both interventions
together (Montgomery et al., 2003). Similarly, factorial MR can
be performed by using combinations of genetic variants to attain
unconfounded estimates of the effect of co-occurrence of the
two drug targets on disease (Davey Smith and Hemani, 2014).
In glioma research if we have two drug targets and we want
to know the combined effects of these two drugs on glioma,
then we can apply factorial MR. Factorial MR can assess the
antitumor efficacy of drug targets on glioma by investigating
the combination of different targeted drugs (Reardon and Wen,
2006).
Future of MR in Glioma Research
For GWAS and MR of glioma progression to be successful for
the development of drug targets to improve glioma survival, large
scale case-only studies will be required with both progression
and germline genetic data. RCTs offer a potential reservoir
of data for such studies; however, due to the rare nature
of glioma, sample size is limited (Vuorinen et al., 2003;
Gehring et al., 2009; U.S.National Library of Medicine, 2018).
A limitation of progression studies is the introduction of
collider bias, discussed in detail in Paternoster et al. (2017).
Collider bias is problematic in MR of disease progression
as a risk factor of interest that causes the disease may be
correlated with other risk factors involved in incidence, and any
association between the index risk factor and progression can
be confounded by these correlated risk factors. If the problems
of sample size and collider bias can be adequately overcome,
GWAS and MR of disease progression offer a promising
opportunity to identify new treatments for glioma that could
enhance survival (Davey Smith et al., 2017). Additionally, an
improved understanding of the molecular changes that drive
glioma progression will allow for opportunities to develop
targeted molecular therapies. At present, although there are
some examples where targeted therapy responses have been
recorded in glioma patients, no targeted therapy has been
approved as an effective treatment in clinical trials (Touat et al.,
2017).
Future research will involve hypothesis free MR, which
make use of omics data. There is a growing body of evidence
showing that epigenetic biomarkers of glioma can be used for
prediction and prognosis. Notably in neuro-oncology the O6-
methylguanine-DNA methyltransferase promoter methylation
can act both a prognostic and predictive biomarker for
glioblastoma (Esteller et al., 2000; Olson et al., 2011; Reifenberger
et al., 2012; Wick et al., 2012). As genetic variants associated with
DNA methylation seem to overlap with expression quantitative
trait loci (eQTLs) at many loci throughout the genome (Bell
et al., 2012; Shi et al., 2014), both DNA methylation and gene
expression may exist on the causal pathway between genetic
variation and disease. The ability to identify epigenetic and
transcriptomic markers for glioma risk and progression could
be important in understanding the underlying mechanisms of
glioma. Using an MR approach, the causal chain between DNA
methylation, gene expression and glioma onset/progression can
be investigated (Relton and Davey Smith, 2012).
Given the lack of large-scale case-only studies with data on
progression and germline genetic data, a priority of research
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in the near term should be to identify causes of glioma onset.
The findings from such studies will be informative for the
design of primary and secondary prevention strategies. The
latter could be particularly valuable for glioma prevention in
high risk populations, such as childhood cancer survivors (who
received radiation therapy), people with genetic syndromes
known to increase risk of glioma and people exposed to known
causal factors because of their occupations. For example, if
a specific dietary factor is found to be causally associated
with a decrease in glioma risk, high risk populations could be
advised to increase their consumption of that specific dietary
factor.
CONCLUSION
Mendelian randomization offers a promising, novel way to
identify risk factors and drug targets for glioma to both inform
public health policy for prevention, as well as, allowing the
development of therapeutic approaches to improve prognosis.
The latter will require the development of large-scale case-
only studies with data on progression and germline genetic
data.
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